![Isabelle de Azevedo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Isabelle de Azevedo
Vorstandsvorsitzender bei Adare Pharmaceuticals SAS
Profil
Isabelle de Azevedo has a current job as Co-Managing Director at Adare Pharmaceuticals SAS.
Aktive Positionen von Isabelle de Azevedo
Unternehmen | Position | Beginn |
---|---|---|
Adare Pharmaceuticals SAS
![]() Adare Pharmaceuticals SAS Pharmaceuticals: MajorHealth Technology Adare Pharmaceuticals SAS offers effective abuse deterrence testing services to help develop formulations that cannot be misused by consumers. The private company is based in Houdan, France. The French company is a technology-driven cdmo providing product development through commercial manufacturing expertise focused on oral dosage forms for the pharmaceutical industry. Adare's technologies provide oral dose forms with taste masking and a modified release profile, among other capabilities. It was founded in 2015, and the CEOs are Gilles Chauviere, Isabelle de Azevedo, Michael Ryan, and Thomas Sellig. | Vorstandsvorsitzender | 03.12.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Adare Pharmaceuticals SAS
![]() Adare Pharmaceuticals SAS Pharmaceuticals: MajorHealth Technology Adare Pharmaceuticals SAS offers effective abuse deterrence testing services to help develop formulations that cannot be misused by consumers. The private company is based in Houdan, France. The French company is a technology-driven cdmo providing product development through commercial manufacturing expertise focused on oral dosage forms for the pharmaceutical industry. Adare's technologies provide oral dose forms with taste masking and a modified release profile, among other capabilities. It was founded in 2015, and the CEOs are Gilles Chauviere, Isabelle de Azevedo, Michael Ryan, and Thomas Sellig. | Health Technology |